Brief: Natco Pharma Gets Final Approval For ANDA For Tipiracil Hydrochloride And Trifluridine
16/06/2023 04:35
June 16 (Reuters) - Natco Pharma Ltd NATP.NS :
* FINAL APPROVAL FOR ANDA FOR TIPIRACIL HYDROCHLORIDE AND
TRIFLURIDINE TABLETS FROM U.S. FDA
Source text for Eikon: ID:nNSE95tT
Further company coverage: NATP.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees